PureTech Health (LON:PRTC) Stock Price Down 12.4% – What’s Next?

PureTech Health plc (LON:PRTC) shares traded down 12.4% on Wednesday . The company traded as low as GBX 100.40 ($1.31) and last traded at GBX 103 ($1.35). 3,018,245 shares changed hands during mid-day trading, an increase of 192% from the average session volume of 1,035,028 shares. The stock had previously closed at GBX 117.60 ($1.54).

Analyst Ratings Changes

Separately, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 455 ($5.96) price objective on shares of PureTech Health in a research note on Monday, December 16th.

PureTech Health Stock Performance

The firm’s 50-day simple moving average is GBX 135.24 and its two-hundred day simple moving average is GBX 148.08. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82. The stock has a market capitalization of £354.45 million, a PE ratio of -4.84 and a beta of 1.02.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.